SANTA FE, N.M., Dec. 1, 2011 /PRNewswire/ -- Sigma Labs, Inc. (OTCBB: SGLB) announced today that its collaborative work with a dental implant manufacturer has resulted in the filing of a potentially ground-breaking patent for a new manufacturing technology that appears to significantly improve integration between an implant and bone.
Richard Mah, CEO of Sigma Labs, states that "this may be a potential game-changer for dental implants and possibly for other prosthetics by reducing the healing time without the need for coatings or additives used by other manufacturers."
An officer of OmegaTi Bio, Inc., a participating member of the research team, confirms that "dental implants made using his breakthrough manufacturing technology are integrating very well within a four week time period during preclinical trials. There have been fewer indications of pain, or inflammation and minimal bone remodeling after implantation as compared to current dental implant technology."
Mark Cola, President of Sigma Labs, states that "we are initiating additional trials for further evaluation as well as planning for successful product introduction and launch into the $4B worldwide implant market."
About Sigma Labs, Inc.
Sigma Labs, Inc. comprises leading scientists and engineers from Los Alamos National Laboratory with over 75 years of combined industrial R&D experience. They develop manufacturing and materials technologies and R&D solutions for first-tier integrators like Boeing, Honeywell, Pratt & Whitney, and other commercial firms around the globe. Sigma Labs, Inc. has current contracts with Federal Government and private industry clients to develop technologies from their conception through the design, building, and testing of prototype systems by integrating sensing, software, materials and manufacturing technology risk-reduction solutions. Visit Sigma Labs at www.sigmalabsinc.com which includes the Company's recently filed quarterly report on Form 10-Q.
This news release contains forward-looking statements that reflect Management's current views about future events and financial performance. Forward-looking statements often contain words such as "expects," "anticipates," "intends," "believes" or "will." Our forward-looking statements are subject to a number of risks and uncertainties that may cause actual results and events to differ materially from those projected in the forward-looking statements. Risks and uncertainties that could adversely affect us include, without limitation, the loss of major customers, our failure to obtain new contracts, our inability to patent products or processes, our infringement of patents held by others, our inability to finance our business and the other risks and uncertainties that are discussed in our most recent filings with the Securities and Exchange Commission, including our most recent annual report on Form 10-K and our Report on Form 8-K that was filed in connection with the transaction we recently completed with B6 Sigma. The forward-looking statements in this news release are made only as of the date of this news release. We undertake no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Sigma Labs, Inc.